Prostate-Specific Antigen
Research News and Information

Sunday, November 22, 2009

Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.

30 Oct 2009 BACKGROUND: Dutasteride is commonly used in patients that are also at risk for prostate cancer (PCa). Therefore, the influence of dutasteride on PCa markers has to be studied. To date, only the effect of dutasteride on serum prostate-specific ... Read more...

Rethinking screening for breast cancer and prostate cancer.

19 Oct 2009 After 20 years of screening for breast and prostate cancer, several observations can be made. First, the incidence of these cancers increased after the introduction of screening but has never returned to prescreening levels. Second, the increase in ... Read more...

Prostate cancer: a newly discovered route for testosterone to reach the prostate : Treatment by super-selective intraprostatic androgen deprivation.

29 Sep 2009 The prostate, an androgen-regulated exocrine gland, is an integral part of the male reproductive system which has an essential function in sperm survival and motility in its long hostile route to meet and fertilise the egg in the Fallopian tube. ... Read more...

Latest indexed articles for 'Prostate-Specific Antigen'

These are the very latest articles for this heading:

• In reply to Dr. Lee: are prostate cancers created equal? 13 Nov 2009
• Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study. 30 Oct 2009
• Prostate specific antigen. Prostate screening in France. 19 Oct 2009
• Rethinking screening for breast cancer and prostate cancer. 19 Oct 2009
• Prostate cancer: a newly discovered route for testosterone to reach the prostate : Treatment by super-selective intraprostatic androgen deprivation. 29 Sep 2009
• Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. 29 Sep 2009
• Modeling the effects of obesity and weight gain on PSA velocity. 29 Sep 2009
• Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study). 26 Sep 2009
• A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices. 26 Sep 2009
• Shared decision making for prostate cancer screening: do patients or clinicians have a choice? 26 Sep 2009
• Weighing the benefits and downsides of prostate-specific antigen screening. 26 Sep 2009
• Prostate specific antigen best practice statement: 2009 update. 22 Sep 2009
• Screening for prostate cancer remains controversial. 22 Sep 2009
• Prostate specific antigen for detecting early prostate cancer. 22 Sep 2009
• Prostate specific antigen for early detection of prostate cancer: longitudinal study. 22 Sep 2009
• T-cell recognition of prostatic peptides in men with chronic prostatitis/chronic pelvic pain syndrome. 15 Sep 2009
• Duration of androgen suppression in prostate cancer. 15 Sep 2009
• Editorial comment. 14 Sep 2009
• Editorial comment. 14 Sep 2009
• Editorial comment. 14 Sep 2009

See a longer list of these articles.

Technical information about 'Prostate-Specific Antigen'

Definition: A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.

Registry Number: EC 3.4.21.77

Descriptor UI: D017430

Alternative terms: Prostate-Specific Antigen; hK3 Kallikrein; Kallikrein, hK3; Seminin; Prostate Specific Antigen; Semenogelase; gamma-Seminoprotein; gamma Seminoprotein; Kallikrein hK3;

Related Mesh Headings: Prostatic Neoplasms;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications;

Tree Number: D08.811.277.656.300.760.442.750; D12.776.866.249.500; D23.050.285.625; D23.101.840.625;

Online Note: use PROSTATE-SPECIFIC ANTIGEN (NM) to search PROSTATE CANCER SPECIFIC ANTIGENS 1982-92 & SEMENOGELASE 1980-95

History Note: 93; was PROSTATE CANCER SPECIFIC ANTIGENS (NM) 1982-92; SEMENOGELASE was NM 1976-95

Technical Notes: do not confuse with prostate-specific acid phosphatase ( = PROSTATE + ACID PHOSPHATASE)